Large Study Links Continuous Glucose Monitoring to 45% Lower Mortality in Type 2 Diabetes Patients on Insulin

At the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, researchers presented findings from an analysis of more than 140 million electronic health records. The target trial emulation study, which matched 13,935 adults with type 2 diabetes initiating continuous glucose monitoring against an equal number of non-users on basal insulin, revealed a 45% lower risk of death from any cause at 12 months for those using the technology.[1][2][3]

Continuous glucose monitors (CGMs) use a small sensor worn on the skin to measure interstitial glucose levels, transmitting real-time readings to a mobile device or dedicated reader. While the technology has transformed care for type 1 diabetes by reducing hypoglycemic episodes and improving time-in-range, its long-term impact on major clinical outcomes for type 2 diabetes patients on basal insulin has remained less certain. The new data provides the first large-scale observational evidence linking advanced CGM technologies to a reduced risk of mortality and cardiovascular events in this specific population.[2][3]

The survival benefits persisted well beyond the first year. At 24 months, the risk of death from any cause remained 36% lower among CGM users, with mortality rates of 2.12% compared to 3.26% for non-users. The study also tracked cardiovascular complications, finding that the risk of a first major macrovascular event—such as a myocardial infarction, stroke, or heart failure—was 26% lower at 12 months and 24% lower at 24 months.[1][2][3]

Heart failure hospitalizations saw particularly steep declines, dropping by 54% at 12 months and 47% at 24 months among those using continuous glucose monitors. A separate observational study highlighted by Abbott reinforced these findings, showing that acute diabetes-event hospitalizations were nearly halved among adults with type 2 diabetes on basal insulin who used the company's Libre technology.[1][2][3]

To account for potential confounding variables, investigators used the Truveta platform to match participants across 29 baseline characteristics, including age, diabetes duration, HbA1c levels, comorbidities, and medication use. The average age of the participants was 58 years, and 47% were female. The findings remained consistent across multiple sensitivity analyses, including those that excluded the COVID-19 period and early deaths occurring within the first 90 days.[2][3]

Despite the rigorous matching process, the study's observational design cannot definitively establish causality. "Our study suggests that CGM can make a real difference to the long-term health of people living with type 2 diabetes who require insulin and may help reduce the risk of early death," said lead investigator Dr. Jochen Seufert of the University Hospital of Freiburg. However, Seufert and his team noted that unmeasured confounding factors might still influence the results, and changes to medications during the follow-up period were not examined.[2][3]

Globally, an estimated 30 million people with type 2 diabetes require insulin therapy, and consistently high glucose levels significantly increase the risk of severe complications like heart disease and stroke. The gap in achieving glycemic targets contributes to an estimated $217 billion in annual diabetes-related healthcare costs in the United States alone.[1][3]

For patients managing type 2 diabetes on basal insulin, the findings offer a reassuring signal that adopting a continuous glucose monitor may provide protective benefits that extend beyond daily convenience. While researchers work to confirm the exact mechanisms through prospective trials, the current data strengthens the clinical argument for expanding access to the technology. The focus in diabetes care is increasingly shifting from merely tracking daily numbers to utilizing tools that actively support long-term cardiovascular health and survival.[2][3][4]